13F Holdings
中文EN

EOCN EoCene Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1595353 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026-06-30), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-30.1%
TTM EPS YoY-182.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-68.2%
ROA-55.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets30.3%
Debt / equity0.00x
Current ratio4.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$4.87M$2.98M$3.57M$12.99M$27.22M
SG&A expense$3.64M$3.30M$3.92M$4.66M$5.66M
Pretax income—$7.52M$6.91M$17.87M-$32.47M
Income tax$0————
Net income-$10.31M-$7.52M-$6.91M-$17.87M-$32.47M
EPS (basic)2.398.0830.00127.8019.80
EPS (diluted)2.398.0830.00127.8019.80
Weighted avg. shares (diluted)4.31M930,822230,795139,6821.64M
Balance sheet
Cash & equivalents$3.98M$4.65M$2.86M$2.02M$2.88M
Short-term investments$7.03M$7.18M$7.53M$11.77M$31.93M
Receivables—$672,000$480,000$825,000$1.12M
Current assets$18.63M$16.12M$13.24M$14.72M$36.05M
PP&E, net——$83,000$114,000$145,000
Total assets$18.63M$18.50M$16.63M$16.56M$36.60M
Current liabilities$2.85M$2.17M$2.75M$3.09M$5.88M
Total liabilities$2.85M$2.17M$2.75M$3.14M$6.11M
Shareholders' equity$15.78M$16.33M$13.88M$13.42M$30.50M
Shares outstanding822,6741.66M573,7411.69M25.09M
Cash flow statement
Operating cash flow-$6.32M-$5.88M-$6.14M-$18.50M-$32.89M
Capital expenditure———$4,000$11,000
Free cash flow———-$18.50M-$32.90M
Investing cash flow-$3.38M-$1.11M$800,000$17.56M$11.46M
Financing cash flow$9.03M$8.79M$6.18M$70,000$17.37M
Depreciation & amortization—$83,000$31,000$35,000$42,000
Stock-based compensation$546,000$531,000$892,000$1.30M$1.89M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.